RE:RE:CG Oncology is worth 7x more than usStocknbonds458 ... Valuation versus valuation.
Sept. 2022, CG Oncology was valued at 407M$US. We are currently valued at 49M$US (216M shares @0.23$US).
407/59 = 8.8x
If CG Oncology goes public via an IPO (and this could soon become reality), it will probably be worth a bit more than its Sept. 2022 valuation of 407M$US.
FDA approval is a no-brained for the BCG-unresponsive in combo with Keytruda as part an interview with Dr. Kamat, so their valuation should approach 1B$US+ because of that.
CG Oncology is only in the bladder indication, with 3 clinical trials ongoing:
- 2 in NMIBC (BCG naive and BCG-unresponsive)
-1 in MIBC
So quite a reasonable one to compare against.
One thing's for sure, our 60M$US valuation is not at the proper level, especially with our efficacy data and 50% into a pivotal Ph. 2.
So lots of catch-up to do. Breakthrough designation will rectify this a bit.